Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 17/20 | 0.61 |
| ▸ | KCNK9 | Q9NPC2 | 17/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22636019 | 0.94 | KCNK3 (0.68) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| SCHEMBL22636358 | 0.92 | KCNK3 (0.68) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| SCHEMBL19807885 | 0.88 | KCNK3 (0.75) | KCNK3KCNK9 | |
| SCHEMBL19807887 | 0.88 | KCNK3 (0.73) | KCNK3KCNK9KDM4E | |
| SCHEMBL19807884 | 0.87 | KCNK3 (0.76) | KCNK3KCNK9KDM4E | |
| SCHEMBL19807866 | 0.86 | KCNK3 (0.77) | KCNK3KCNK9 | |
| SCHEMBL19807886 | 0.86 | KCNK3 (0.81) | KCNK3KCNK9 | |
| SCHEMBL19807651 | 0.86 | KCNK3 (0.72) | KCNK3KCNK9SLC2A1 | |
| SCHEMBL30418662 | 0.85 | KCNK3 (0.67) | KCNK3KCNK9KDM4EGAASLC2A1 | |
| SCHEMBL25423903 | 0.85 | KCNK3 (0.76) | KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3965766-A1 | COMBINATION OF AN ?2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | Bayer Aktiengesellschaft (DE) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020225185-A1 | COMBINATION OF AN α2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONISTS WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2020-11-12 | — | — | WO | disclosed |